Meta-analysis of Efficacy and Safety Outcomes Associated With the Basal-Plus Regimen of Insulin Glargine and Insulin Glulisine among Type 2 Diabetes Patients With HbA1c≥8%

被引：0

|

作者：

Raccah, Denis

Lin, Jay

Bahloul, Amar

Wang, Edward

Penfornis, Alfred

机构：

来源：

DIABETES | 2012年 / 61卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2464-PO

引用

收藏

页码：A620 / A620

页数：1

相关论文

共 50 条

[31] Insulin dose and weight profiles of pre- and post-meal insulin glulisine in a basal-bolus regimen with insulin glargine in patients with Type 1 diabetes
Klaff, L
Rosenstock, J
Garg, S
Souhami, E
Ways, K
[J]. DIABETOLOGIA, 2004, 47 : A300 - A300
[32] EFFICACY OF LIRAGLUTIDE COMPARED TO EXENATIDE AND INSULIN GLARGINE IN PATIENTS WITH DIABETES TYPE 2: A META-ANALYSIS
Fadipe, J. J.
[J]. VALUE IN HEALTH, 2012, 15 (07) : A467 - A467
[33] Efficacy and Safety of Insulin Aspart 30 and Insulin Degludec/Aspart vs. Basal Insulin in Patients with Type 2 Diabetes: A Meta-analysis
Mishriky, Basem M.
Tanenberg, Robert J.
Cummings, Doyle M.
[J]. DIABETES, 2017, 66 : A252 - A252
[34] GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis
Castellana, Marco
Cignarelli, Angelo
Brescia, Francesco
Laviola, Luigi
Giorgino, Francesco
[J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35 (01)
[35] Efficacy and Safety of Fast-Acting Insulin Aspart According to Baseline HbA1c in Adults with Type 2 Diabetes Treated with a Basal-Bolus Regimen
Franek, Edward
Ekelund, Magnus
Thorisdottir, Olof
Jang, Hak Chul
Lalic, Katarina
Rathor, Naveen
Rose, Ludger
Gonzalez, Alfonso Soto
Silver, Robert J.
Lane, Wendy
[J]. DIABETES, 2020, 69
[36] Expanding the Basal-Plus Regimen: Basal Insulin plus Lixisenatide Is More Likely to Achieve the Composite Outcome Of Hba1c <7%, No Documented Symptomatic Hypoglycemia and No Weight Gain Compared With Basal plus Prandial Insulin
Rosenstock, Julio
Germe, Maeva
Wang, Edward
Lin, Jay
Bonadonna, Riccardo C.
De Pablos-Velasco, Pedro
Roussel, Ronan
Raccah, Denis
[J]. DIABETES, 2013, 62 : A262 - A262
[37] Basal insulin and oral antidiabetic therapy (BOT)+ a single dose of insulin glulisine (BOT+) reduces HbA1c and blood glucose values in patients with type 2 diabetes
Lankisch, Mark
Ferlinz, Kaus
Scherbaum, Werner A.
[J]. DIABETES, 2007, 56 : A51 - A52
[38] Basal insulin and oral antidiabetic therapy (BOT)+ a single dose of insulin glulisine (BOT+) reduces HbA1c and blood glucose values in patients with type 2 diabetes
Lankisch, M.
FerlinZ, K.
Scherbaum, W. A.
[J]. DIABETOLOGIA, 2007, 50 : S404 - S405
[39] Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin
Jammah, Anwar Ali
[J]. PRIMARY CARE DIABETES, 2021, 15 (01) : 132 - 137
[40] Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials
Giugliano, D.
Maiorino, M.
Bellastella, G.
Chiodini, P.
Esposito, K.
[J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (05) : 602 - 612

← 1 2 3 4 5 →